KBLB Stock Overview
Engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kraig Biocraft Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.09 |
| 52 Week High | US$0.16 |
| 52 Week Low | US$0.025 |
| Beta | 0.72 |
| 11 Month Change | -2.44% |
| 3 Month Change | -9.09% |
| 1 Year Change | 200.00% |
| 33 Year Change | 32.35% |
| 5 Year Change | -53.56% |
| Change since IPO | 80.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| KBLB | US Chemicals | US Market | |
|---|---|---|---|
| 7D | -4.5% | 3.2% | 2.2% |
| 1Y | 200.0% | 13.6% | 32.6% |
Return vs Industry: KBLB exceeded the US Chemicals industry which returned 11.6% over the past year.
Return vs Market: KBLB exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| KBLB volatility | |
|---|---|
| KBLB Average Weekly Movement | 6.7% |
| Chemicals Industry Average Movement | 5.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KBLB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KBLB's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 41 | Kim Thompson | www.kraiglabs.com |
Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. Its primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. The company’s products are used in military and police, and defense applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry.
Kraig Biocraft Laboratories, Inc. Fundamentals Summary
| KBLB fundamental statistics | |
|---|---|
| Market cap | US$90.55m |
| Earnings (TTM) | -US$3.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-24.1x
P/E RatioIs KBLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KBLB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.87m |
| Earnings | -US$3.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -22.0% |
How did KBLB perform over the long term?
See historical performance and comparison